(±)-2-(3-methyl-4-nitrophenyl)propanoic acid | 83528-11-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: (±)-2-(3-methyl-4-nitrophenyl)propanoic acid
• 英文别名: 2-(3-Methyl-4-nitrophenyl)propanoic acid
• CAS: 83528-11-4
• 化学式: C₁₀H₁₁NO₄
• 分子量: 209.202
• InChiKey: VXEOJYKDIYIGBW-UHFFFAOYSA-N

物化性质

• 沸点：
  409.7±40.0 °C(Predicted)
• 密度：
  1.324±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (±)-2-(3-methyl-4-nitrophenyl)propanoic acid 在 盐酸 、 4-二甲氨基吡啶 、 硫酸 、 palladium 10% on activated carbon 、 甲酸铵 、 palladium diacetate 、 potassium carbonate 、 sodium nitrite 作用下， 以 1,4-二氧六环 、 甲醇 、 乙二醇甲醚 、 水 、 乙腈 为溶剂， 反应 49.5h， 生成 (±)-methyl 2-[4-[3-(hexylcarbamoyloxy)phenyl]-3-methylphenyl]propanoate
  参考文献：
  名称：

  Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies

  摘要：

  Non-steroidal anti-inflammatory drugs (NSAIDs) exert their pharmacological effects by inhibiting cyclooxygenase (COX)-1 and COX-2. Though widely prescribed for pain and inflammation, these agents have limited utility in chronic diseases due to serious mechanism-based adverse events such as gastrointestinal damage. Concomitant blockade of fatty acid amide hydrolase (FAAH) enhances the therapeutic effects of the NSAIDs while attenuating their propensity to cause gastrointestinal injury. This favorable interaction is attributed to the accumulation of protective FAAH substrates, such as the endocannabinoid anandamide, and suggests that agents simultaneously targeting COX and FAAH might provide an innovative strategy to combat pain and inflammation with reduced side effects. Here, we describe the rational design and structure-active relationship (SAR) properties of the first class of potent multitarget FAAH-COX inhibitors. A focused SAR exploration around the prototype 10r (ARN2508) led to the identification of achiral (18b) as well as racemic (29a-c and 29e) analogs. Absolute configurational assignment and pharmacological evaluation of single enantiomers of 10r are also presented. (S)-(+)-10r is the first highly potent and selective chiral inhibitor of FAAH-COX with marked in vivo activity, and represents a promising lead to discover novel analgesics and anti-inflammatory drugs. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.12.036
• 作为产物：
  描述：

  5-氯-2-硝基甲苯 在 sodium hydroxide 、 sodium hydride 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.33h， 生成 (±)-2-(3-methyl-4-nitrophenyl)propanoic acid
  参考文献：
  名称：

  非甾体抗炎药。2。[（杂芳基氨基）苯基]链烷酸。

  摘要：

  制备了具有吡啶，喹啉或嘧啶作为杂芳基部分的一系列[（杂芳基氨基）苯基]链烷酸作为潜在的抗炎剂。其中，2- [4-（2-吡啶基氨基）苯基]丙酸（14b）具有出色的抗炎和镇痛活性，较少引起胃副反应。讨论了构效关系。

  DOI：

  10.1021/jm00356a019

文献信息

• [EN] 2-PHENYL BENZOYLAMIDES<br/>[FR] 2-PHÉNYLBENZOYLAMIDES
  申请人：PFIZER

  公开号：WO2011145022A1

  公开（公告）日：2011-11-24

  Compounds of Formula I that inhibit microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion and their uses in the treatment of diseases linked thereto in animals are described herein.

  公式I的化合物能够抑制微粒体甘油三酯转运蛋白（MTP）和/或载脂蛋白B（Apo B）的分泌，以及它们在治疗与这些疾病相关的动物疾病中的应用，在本文件中有所描述。
• COMPOUNDS AND THERAPEUTIC USES THEREOF
  申请人：Kumar Dange Vijay

  公开号：US20120122840A1

  公开（公告）日：2012-05-17

  The invention relates to compounds, pharmaceutical compositions, and uses thereof, including therapeutic uses thereof, such as methods useful for treating cancer.

  本发明涉及化合物、药物组合物及其用途，包括治疗用途，例如用于治疗癌症的有用方法。
• HINO, KATSUHIKO;NAKAMURA, HIDEO;NAGAI, YASUTAKA;UNO, HITOSHI;NISHIMURA, H+, J. MED. CHEM., 1983, 26, N 2, 222-226
  作者：HINO, KATSUHIKO、NAKAMURA, HIDEO、NAGAI, YASUTAKA、UNO, HITOSHI、NISHIMURA, H+

  DOI：——

  日期：——
• Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies
  作者：Marco Migliore、Damien Habrant、Oscar Sasso、Clara Albani、Sine Mandrup Bertozzi、Andrea Armirotti、Daniele Piomelli、Rita Scarpelli

  DOI：10.1016/j.ejmech.2015.12.036

  日期：2016.2

  Non-steroidal anti-inflammatory drugs (NSAIDs) exert their pharmacological effects by inhibiting cyclooxygenase (COX)-1 and COX-2. Though widely prescribed for pain and inflammation, these agents have limited utility in chronic diseases due to serious mechanism-based adverse events such as gastrointestinal damage. Concomitant blockade of fatty acid amide hydrolase (FAAH) enhances the therapeutic effects of the NSAIDs while attenuating their propensity to cause gastrointestinal injury. This favorable interaction is attributed to the accumulation of protective FAAH substrates, such as the endocannabinoid anandamide, and suggests that agents simultaneously targeting COX and FAAH might provide an innovative strategy to combat pain and inflammation with reduced side effects. Here, we describe the rational design and structure-active relationship (SAR) properties of the first class of potent multitarget FAAH-COX inhibitors. A focused SAR exploration around the prototype 10r (ARN2508) led to the identification of achiral (18b) as well as racemic (29a-c and 29e) analogs. Absolute configurational assignment and pharmacological evaluation of single enantiomers of 10r are also presented. (S)-(+)-10r is the first highly potent and selective chiral inhibitor of FAAH-COX with marked in vivo activity, and represents a promising lead to discover novel analgesics and anti-inflammatory drugs. (C) 2015 Elsevier Masson SAS. All rights reserved.
• Nonsteroidal antiinflammatory agents. 2. [(Heteroarylamino)phenyl]alkanoic acids
  作者：Katsuhiko Hino、Hideo Nakamura、Yasutaka Nagai、Hitoshi Uno、Haruki Nishimura

  DOI：10.1021/jm00356a019

  日期：1983.2

  A series of [(heteroarylamino)phenyl]alkanoic acids having pyridine, quinoline, or pyrimidine as the heteroaryl moiety was prepared as potential antiinflammatory agents. Among them, 2-[4-(2-pyridylamino)phenyl]propionic acid (14b) showed excellent antiinflammatory and analgesic activities with less tendency to cause gastric side effects. Structure-activity relationships are discussed.

  制备了具有吡啶，喹啉或嘧啶作为杂芳基部分的一系列[（杂芳基氨基）苯基]链烷酸作为潜在的抗炎剂。其中，2- [4-（2-吡啶基氨基）苯基]丙酸（14b）具有出色的抗炎和镇痛活性，较少引起胃副反应。讨论了构效关系。